GLP-1 Help!

While the links between GLP-1 drugs and reduced risk of adverse heart health are promising, Stricoff says, it is crucial to recognize that these medications primarily address the symptoms and consequences of type 2 diabetes rather than the root causes of the disease. Now, a new study has shown that a class of diabetes medications is associated with fewer major adverse cardiovascular events. Furthermore, the study did not examine the long-term safety and efficacy of these medications, she points out. "GLP-1 receptor agonists not only lower blood sugar levels but also have additional cardiovascular benefits," she points out. Materials and Methods: This study was carried out retrospectively. The study found GLP-1s were associated with a 20% reduced risk of major cardiovascular events in older adults when compared to other diabetes drugs. So, GLP-1s aside, what else can you do to improve your heart health? "Unhealthy lifestyle choices, such as a poor diet, physical inactivity, and smoking, are common risk factors for both type 2 diabetes and heart disease, and these factors can exacerbate the risk of developing heart disease in people with diabetes," she explains. According to Stricoff, the reason someone with type 2 diabetes might experience a reduced risk of cardiovascular disease when taking a GLP-1 drug compared to a DPP4 inhibitor hinges on the effects these drugs have on cardiovascular risk factors.



Importantly, however, those taking Steglatro had a 30% lower risk of heart failure than did participants not taking Steglatro (see graph below). However, differential GIP secretion and GIP duodenal expression were found between RYGB and PdIT. Background: The role of the ileum and Glucagon Like Peptide-1 (GLP-1) secretion in the pathophysiological processes underlying the effects of Roux-en-Y gastric bypass (RYGB) on type 2 Diabetes mellitus (T2DM) improvement has been previously determined. Increased beta-cell mass was found in RYGB and PdIT animals as well as similar GLP-1 secretion and GLP-1 intestinal expression. To clarify this aspect, we compared the pathophysiological mechanisms triggered by RYGB, ColonBroom brand which implies the early arrival of food to the ileum with duodenal exclusion, and through pre-duodenal ileal transposition (PdIT), with early arrival of food to the ileum but without duodenal exclusion, in a nondiabetic rodent model. "Nutrition education is a vital component of this approach, as it empowers patients to make informed decisions about their food choices, understand the impact of diet on their health, and adopt healthier eating habits that can be sustained even in the absence of medication," she surmises. Specifically, Scott advises following a diet that is low in saturated and trans fats, sodium, and added sugars, and high in fiber, whole grains, fruits, and vegetables.



Additionally, Scott notes that the study population consisted of U.S. Thus, the present study investigated the protective and therapeutic effects of liraglutide on CCl4-induced hepatotoxicity and the underlying mechanisms and pathways that are involved in these actions. Similarly, Crystal Scott, a registered dietitian at Top Nutrition Coaching, says the results of this study are consistent with previous evidence on the links between GLP-1 drugs and cardiovascular health in people with type 2 diabetes. In other words, these results translate to approximately three fewer heart failure, heart attack, or stroke events per 1,000 people using a GLP-1 medication for a year. SGLT2 inhibitors have also shown encouraging results in individuals with OSA, while individuals with OSA often experience multiple comorbidities that are clinical indications for their administration (Table II). "GLP-1 inhibitors have emerged as a promising treatment option for individuals with type 2 diabetes, demonstrating not only effective blood sugar control but also additional benefits like weight loss and reduced risk of cardiovascular disease," says Bari Stricoff, a registered dietitian at Well Easy. New research has shown that GLP-1 drugs used for the treatment of type 2 diabetes are associated with fewer adverse heart health events.



If I were to tell you that there exists a miraculous elixir derived from the saliva of a monster and it may aid us in the treatment of Parkinson’s disease, would you think me mad? "Firstly, obesity is a major risk factor for cardiovascular disease, and GLP-1 receptor agonists can promote weight loss by reducing appetite and increasing satiety," Stricoff explains. If you’re taking a GLP-1 weight loss drug, make sure you tell your healthcare provider about any other medications or supplements that you’re taking. Experts say these medications may lower the risk of adverse heart health because of their effects on weight loss, blood pressure, and lipid profiles. Saghebjoo M, Farrokhi-Fard M, Hedayati M, Sadeghi-Tabas S. The effect of high-intensity interval training and L-arginine supplementation on the serum levels of adiponectin and lipid profile in overweight and obese young men. "GLP-1 medications can also have a positive effect on lipid profiles, such as reducing triglyceride levels, which may contribute to a reduced risk of cardiovascular events," Stricoff adds. Medications often come with a long list of scary side effects, so it’s certainly promising that GLP-1 drugs are linked with a lower risk of adverse cardiac events. The study, ColonBroom brand conducted at Vanderbilt University Medical Center, found that GLP-1 drugs like Ozempic (semaglutide) resulted in lower instances of Major cardiovascular events (MACE) than DPP4 inhibitors (another type of diabetes drug) in older veterans with no prior heart disease.